A Study of Regorafenib in Advanced Pancreatic Cancer Patients
Public ClinicalTrials.gov record NCT02080260. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study tests regorafenib as a single agent in the treatment of metastatic pancreatic cancer patients who have progressed after prior chemotherapy with gemcitabine. The prognosis for these patients is particularly grim, no other standard treatment options exist, and novel approaches are desperately needed.
Study identification
- NCT ID
- NCT02080260
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 5, 2014
- Primary completion
- Jun 27, 2017
- Completion
- Jun 27, 2017
- Last update posted
- Apr 20, 2022
2014 – 2017
United States locations
- U.S. sites
- 12
- U.S. states
- 2
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Levine Cancer Institute-Albemarle | Albemarle | North Carolina | 28001 | — |
| Levine Cancer Institute-South Tryon | Charlotte | North Carolina | 28203 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Levine Cancer Institute - Pineville | Charlotte | North Carolina | 28210 | — |
| Levine Cancer Institute - Southpark | Charlotte | North Carolina | 28211 | — |
| Levine Cancer Institute - Mallard Creek | Charlotte | North Carolina | 28262 | — |
| Levine Cancer Institute - University | Charlotte | North Carolina | 28262 | — |
| Levine Cancer Institute - Ballantyne | Charlotte | North Carolina | 28277 | — |
| Levine Cancer Institute - Concord | Concord | North Carolina | 28025 | — |
| Levine Cancer Institute-Monroe | Monroe | North Carolina | 28112 | — |
| Levine Cancer Institute - Cleveland | Shelby | North Carolina | 28150 | — |
| Low Country Hematology Oncology | Charleston | South Carolina | 29406 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02080260, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2022 · Synced Sep 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02080260 live on ClinicalTrials.gov.